Skip to content

Natera and CytoDyn Collaborate on ctDNA in Colorectal Cancer

Natera and CytoDyn have announced a strategic collaboration aimed at advancing the development and analysis of circulating tumor DNA (ctDNA) in metastatic colorectal cancer. This partnership seeks to evaluate ctDNA dynamics and generate molecular insights relevant to the treatment of the disease.

AUSTIN, Texas & VANCOUVER, Wash.–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, today announced a strategic collaboration to evaluate circulating tumor DNA (ctDNA) dynamics and generate real-world molecular insi